Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-05-02 Declaration of Voting R…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Informations relatives au nombre total de droits de vote et d'actions' and explicitly references French regulatory articles (Article L. 233-8 II du Code de commerce and Article 223-16 du Règlement général de l'Autorité des Marchés Financiers). It provides a table detailing the total number of shares and voting rights as of a specific date (March 31, 2025). This content directly relates to official disclosures regarding the capital structure and voting rights, which falls under general regulatory announcements or specific capital/share information. Since it is a formal disclosure of share/voting rights data, it aligns closely with 'Share Issue/Capital Change' (SHA) or potentially a general 'Regulatory Filing' (RNS). Given the specific focus on the total number of voting rights and shares, SHA is a strong candidate, but the nature of this specific disclosure (voting rights count mandated by AMF) often falls under general regulatory reporting. However, looking at the definitions, 'SHA' covers share issues/capital changes, and 'MRQ' covers major shareholding notifications. This document is a mandatory periodic disclosure of the total share count and voting rights, which is a fundamental aspect of capital structure reporting. In many contexts, this specific type of filing (often called a 'Declaration of the total number of shares and voting rights') is classified as a general regulatory filing or a capital structure update. Given the options, and since it's not a dividend notice (DIV), director dealing (DIRS), or a major shareholder notification (MRQ), and it's a formal regulatory disclosure, RNS (Regulatory Filings) is the most appropriate general category for mandatory, non-specific regulatory data updates, although SHA is also plausible. Given the context of mandatory regulatory reporting of share count, RNS is chosen as the best fit for a general regulatory disclosure not covered by more specific categories like DIV or DIRS.
2025-05-02 French
Sanofi: Information concerning the total number of voting rights and shares - March 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns 'Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce' and article 223-16 of the AMF Regulation. It provides a table detailing the 'Total number of issued shares' and 'Number of real voting rights' as of a specific date (31 March 2025). This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing requirement, often related to capital structure updates or general shareholder information, but it is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a specific regulatory disclosure about the share count. Given the options, this fits best under a general regulatory announcement or a specific capital/share structure update. Since it is a formal disclosure of voting rights and share count, it is most closely related to capital structure changes or mandatory regulatory reporting. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Transaction in Own Shares (POS). The closest fit among the specific codes is related to capital/share structure, but the content is purely about the total number of shares and voting rights, which is a common requirement for regulatory bodies. Since there isn't a specific 'Share Capital Disclosure' code, and it is a formal regulatory notice about voting rights, it falls under the general regulatory filing category (RNS) or potentially a specific capital announcement (CAP/SHA). However, because it is a routine, periodic disclosure of voting rights mandated by French regulation (AMF), and not a transaction (SHA/POS) or a change in management (MANG), RNS (Regulatory Filings) serves as the most appropriate general regulatory fallback for this specific type of mandatory disclosure that doesn't fit the other precise categories like DVA (which is for *results* of a vote, not the total rights count). Given the highly specific nature of the required disclosure (voting rights count), and the lack of a perfect match, RNS is the safest classification for a mandatory regulatory filing that isn't a primary financial report or a specific transaction notice.
2025-05-02 English
6-K
Regulatory Filings
2025-04-30 English
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2025
AGM Information Classification · 99% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and focuses on the outcomes of the "Assemblée Générale Annuelle" (Annual General Meeting - AGM) held on April 30, 2025. Key items discussed are the approval of 2024 accounts, dividend distribution, and board composition changes (renewal and ratification). While it covers AGM outcomes, the format is a press release summarizing the event, not the detailed presentation materials (IP) or the official voting results document (DVA). Since it is a summary announcement related to the AGM, the most fitting category is AGM Information (AGM-R), which covers presentations and materials shared during the AGM. Given the content is a summary of the meeting's decisions, AGM-R is appropriate, although RPA could be considered if it were purely an announcement *about* the release of the full results. However, the content details the key resolutions passed, making AGM-R stronger.
2025-04-30 French
Press Release: Annual General Meeting of April 30, 2025
AGM Information Classification · 99% confidence The document is explicitly titled 'Annual General Meeting of April 30, 2025' and details resolutions adopted during this meeting, such as the approval of 2024 financial statements, dividend distribution, and board composition changes. This content directly aligns with the definition of AGM Information. Although it mentions financial statements and dividends, the primary context is the meeting itself and the outcomes voted upon, making AGM-R the most precise classification over ER, DIV, or 10-K. The document is a press release summarizing the meeting outcomes, not the full presentation materials, but it is clearly focused on the AGM event.
2025-04-30 English
Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces the finalization of a major corporate transaction: the sale of a controlling stake in Sanofi's consumer healthcare division (Opella) to CD&R. This type of announcement, detailing a significant corporate event (divestiture/sale) and providing quotes from management, is characteristic of a corporate news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it announces a significant corporate action (sale/divestiture) that impacts capital structure and strategy, it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release announcing a major transaction that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP), although TAR relates to M&A activity, this is the closing announcement of a divestiture. However, RNS is defined as a 'General regulatory announcement and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' Since this is a press release announcing a transaction completion, and not the detailed legal/financial filing of the transaction itself, RNS is the best fit among the provided codes for a general corporate announcement/press release.
2025-04-30 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.